Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.50EUR
11:35am EDT
Change (% chg)

€0.10 (+0.10%)
Prev Close
€96.40
Open
€96.30
Day's High
€96.97
Day's Low
€95.71
Volume
464,173
Avg. Vol
469,475
52-wk High
€115.20
52-wk Low
€90.00

Latest Key Developments (Source: Significant Developments)

Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer
Tuesday, 20 Jun 2017 08:00am EDT 

June 20 (Reuters) - Merck Kgaa :Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer.Effector Therapeutics - cos plan to initiate Phase 2 study to evaluate EFT508 in combination with avelumab in microsatellite stable relapsed or refractory CRC patients.Effector Therapeutics - Pfizer and Merck KGAA will share clinical study costs with effector.  Full Article

Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma
Thursday, 15 Jun 2017 11:00am EDT 

June 15 (Reuters) - Human longevity Inc : :Human longevity - signed agreement with merck kgaa, darmstadt, germany which operates its biopharmaceutical business as emd serono in u.s. And canada.Human longevity - as part of deal, co's have started joint pilot project to identify treatment response biomarker signatures in patients with advanced melanoma.Human longevity inc says financial terms of deal were not disclosed.  Full Article

Ablynx to receive 15 million euros milestone payment
Monday, 22 May 2017 01:00am EDT 

May 22 (Reuters) - ABLYNX NV ::NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT.ABLYNX ANNOUNCED THAT IT HAS COMPLETED PREPARATION OF A PRE-CLINICAL PACKAGE FOR A NOVEL NANOBODY® (ALX-1141) IN OSTEOARTHRITIS.AS PART OF ONGOING COLLABORATION BETWEEN ABLYNX AND MERCK KGAA <<>>, MERCK HAS ACCEPTED PRE-CLINICAL PACKAGE AND THIS HAS TRIGGERED A EUR 15 MILLION MILESTONE PAYMENT TO ABLYNX.MERCK IS NOW RESPONSIBLE FOR FURTHER CLINICAL DEVELOPMENT OF MOLECULE.  Full Article

Merck KGaA's Pergoveris fertility pen gets EU approval
Wednesday, 10 May 2017 07:22am EDT 

May 10 (Reuters) - Merck KGaA :Says European Commission grants approval for Merck’s new Pergoveris pen for fertility treatment.  Full Article

U.S. FDA grants accelerated approval to Avelumab for Urothelial Carcinoma
Tuesday, 9 May 2017 12:22pm EDT 

May 9 (Reuters) - U.S. FDA::U.S. Food and Drug Administration grants accelerated approval to avelumab for urothelial carcinoma.  Full Article

Merck KGaA acquires Grzybowski Scientific Inventions
Tuesday, 9 May 2017 08:05am EDT 

May 9 (Reuters) - MERCK KGAA ::ACQUIRES GRZYBOWSKI SCIENTIFIC INVENTIONS TO EXPAND CHEMICAL SYNTHESIS OFFERING.FINANCIAL DETAILS OF THE TRANSACTION WERE NOT DISCLOSED.  Full Article

FDA approves treatment for metastatic merkel cell carcinoma
Thursday, 23 Mar 2017 02:28pm EDT 

U.S. FDA: Granted accelerated approval to Bavencio for treatment of adults, pediatric patients 12 years and older with metastatic merkel cell carcinoma .Further clinical trials are required to confirm Bavencio’s clinical benefit.  Full Article

Merck KGaA announces release of two fertility technologies products
Friday, 10 Mar 2017 05:13am EST 

Merck Kgaa :release of 2 fertility technologies products for improved efficiency in assisted reproductive treatment lab, eevatest 3.0, geri humidified incubation.  Full Article

Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on BGB-283
Thursday, 2 Mar 2017 09:00am EST 

Beigene Ltd :Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on continuation option to develop, commercialize BGB-283 outside China.  Full Article

Merck says NICE expands a positive recommendation for Erbitux
Thursday, 2 Mar 2017 02:04am EST 

Merck KGaA :Says NICE expands positive recommendation for Erbitux as first-line treatment for RAS Wild-type mCRC.  Full Article

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

FRANKFURT European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.